Kura Oncology Inc. (NASDAQ:KURA) shares saw strong trading volume on Monday . 436,225 shares traded hands during mid-day trading, a decline of 5% from the previous session’s volume of 457,930 shares.The stock last traded at $4.40 and had previously closed at $5.19.

Several analysts recently commented on the stock. Zacks Investment Research upgraded shares of Kura Oncology from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a research note on Tuesday, March 22nd. Oppenheimer Holdings Inc. reiterated an “outperform” rating and issued a $16.00 price objective on shares of Kura Oncology in a research note on Tuesday, June 21st.

The firm’s market capitalization is $84.82 million. The stock has a 50-day moving average price of $3.12 and a 200 day moving average price of $3.88.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Wednesday, May 11th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.01. On average, equities analysts expect that Kura Oncology Inc. will post ($1.70) EPS for the current year.

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.